Did you know that Tiefenbacher Group is in the final phase of constructing a new, state-of-the-art laboratory and production site for highly potent drugs against cancer and other diseases?
The new complex is located at Tiefenbacher Laboratories in Hyderabad, India, and covers a total area of approximately 4,000 m². It provides laboratories with the latest equipment and full safety measures, as well as an additional production block with special technologies in a GMP-compliant environment. Tiefenbacher Pharmaceuticals (FDF business unit of Tiefenbacher Group) has already more than 20 leading highly potent drugs in its launch pipeline which are planned to be developed and produced in the new facilities.
These investments in infrastructure and technology reflect the company’s commitment to continuously improving healthcare and making high-quality medicines more affordable, more available and better than before. The new site is expected to be fully operational still this year.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
